LN
Therapeutic Areas
Sensorion Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OTOF-GT (SENS-501) | Otoferlin Deficiency | Phase 1/2 |
| GJB2-GT | Early Presbycusis linked to GJB2 | Pre-clinical |
| SENS-401 | Cochlear Preservation after Cochlear Implantation | Phase 2 |
Leadership Team at Sensorion
NO
Nawal Ouzren
Chief Executive Officer
GM
Gilles Mirey
Chief Scientific Officer
BL
Bénédicte Lortat-Jacob
General Counsel & Chief Compliance Officer
DG
Dr. Géraldine Honnet
Chief Medical Officer
KL
Karine Lignel
SVP, Head of Corporate Development & Investor Relations